These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2170626

  • 1. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S, Ortega MP, Priego JG, de Casa-Juana MF, Sunkel C, Sánchez Crespo M.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [Abstract] [Full Text] [Related]

  • 2. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP, García MC, Gijón MA, de Casa-Juana MF, Priego JG, Sanchez Crespo M, Sunkel C.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [Abstract] [Full Text] [Related]

  • 3. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
    Doebber TW, Wu MS, Biftu T.
    J Immunol; 1986 Jun 15; 136(12):4659-68. PubMed ID: 3011900
    [Abstract] [Full Text] [Related]

  • 4. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar 15; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I.
    Arzneimittelforschung; 1991 Jul 15; 41(7):719-24. PubMed ID: 1663352
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug 15; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 7. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
    Rabinovici R, Yue TL, Farhat M, Smith EF, Esser KM, Slivjak M, Feuerstein G.
    J Pharmacol Exp Ther; 1990 Oct 15; 255(1):256-63. PubMed ID: 2213560
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec 15; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
    Wu MS, Biftu T, Doebber TW.
    J Pharmacol Exp Ther; 1986 Dec 15; 239(3):841-5. PubMed ID: 3795043
    [Abstract] [Full Text] [Related]

  • 10. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.
    Sun XM, Hsueh W, Torre-Amione G.
    Am J Pathol; 1990 Apr 15; 136(4):949-56. PubMed ID: 2327475
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
    Sakuma Y, Shirato M, Nagaoka J, Obaishi H, Tsunoda H, Katayama S, Ono H, Katayama K.
    Arzneimittelforschung; 1991 Dec 15; 41(12):1255-9. PubMed ID: 1815526
    [Abstract] [Full Text] [Related]

  • 12. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
    Kuipers B, van der Poll T, Levi M, van Deventer SJ, ten Cate H, Imai Y, Hack CE, ten Cate JW.
    J Immunol; 1994 Mar 01; 152(5):2438-46. PubMed ID: 8133055
    [Abstract] [Full Text] [Related]

  • 13. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K.
    J Pharmacol Exp Ther; 1987 Jul 01; 242(1):263-8. PubMed ID: 3612533
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
    Brecht HM, Adamus WS, Heuer HO, Birke FW, Kempe ER.
    Arzneimittelforschung; 1991 Jan 01; 41(1):51-9. PubMed ID: 1646613
    [Abstract] [Full Text] [Related]

  • 15. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep 01; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 17. Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis.
    He J, Bazan HE.
    Invest Ophthalmol Vis Sci; 2006 Mar 01; 47(3):883-91. PubMed ID: 16505020
    [Abstract] [Full Text] [Related]

  • 18. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.
    Natsume Y, Imanishi N, Koike H, Morooka S.
    Arzneimittelforschung; 1994 Nov 01; 44(11):1208-13. PubMed ID: 7848333
    [Abstract] [Full Text] [Related]

  • 19. Actions of platelet-activating factor on isolated rat hearts.
    Pugsley MK, Salari H, Walker MJ.
    Circ Shock; 1991 Dec 01; 35(4):207-14. PubMed ID: 1663843
    [Abstract] [Full Text] [Related]

  • 20. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.
    Handley DA, Van Valen RG, Melden MK, Flury S, Lee ML, Saunders RN.
    Immunopharmacology; 1986 Aug 01; 12(1):11-6. PubMed ID: 3019921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.